Pearce Michael Cooper 4
4 · PERNIX THERAPEUTICS HOLDINGS, INC. · Filed Nov 23, 2012
Insider Transaction Report
Form 4
Pearce Michael Cooper
Director
Transactions
- Sale
Common Stock
2012-11-21$7.37/sh−3,440$25,356→ 36,667 total - Exercise/Conversion
Employee Stock Option (right to buy)
2012-11-20−17,242→ 47,740 totalExercise: $4.20Exp: 2013-03-09→ Common Stock (17,242 underlying) - Exercise/Conversion
Common Stock
2012-11-21$4.20/sh+3,440$14,448→ 40,107 total - Exercise/Conversion
Common Stock
2012-11-20$4.20/sh+17,242$72,416→ 53,909 total - Sale
Common Stock
2012-11-20$7.23/sh−17,242$124,730→ 36,667 total - Exercise/Conversion
Employee Stock Option (right to buy)
2012-11-21−3,440→ 44,300 totalExercise: $4.20Exp: 2013-03-09→ Common Stock (3,440 underlying)
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 8/16/12.
- [F2]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.01 to $7.35, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.28 to $7.41, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The option which represents a right to purchase a total of 137,500 shares of which 72,518 were purchased prior to 11/20/2012 date, became fully exercisable on 3/9/10.